Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stefano Zoroddu has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plasma SH Concentrations and Mortality in Patients with Newly Diagnosed Idiopathic Pulmonary Fibrosis

    by Panagiotis Paliogiannis, Stefano Zoroddu, Simona Fois, Chiara Scala, Elisabetta Zinellu, Arduino A. Mangoni, Ciriaco Carru, Pietro Pirina, Angelo Zinellu, Alessandro G. Fois

    Introduction. Oxidative stress plays a critical role in the pathogenesis of idiopathic pulmonary fibrosis (IPF), yet its prognostic significance remains unclear. This study investigated the association between plasma sulfhydryl (SH) group concentrations and thiobarbituric acid reactive substances (TBARS), systemic markers of oxidative stress, and mortality in patients with IPF. Materials and methods. Eighty-eight patients with newly diagnosed IPF were recruited between 2016 and 2023 for the purposes of the study. Plasma SH and TBARS were measured at baseline under standardized conditions and normalized to plasma protein content. Survival analyses were performed using Kaplan–Meier curves and Cox regression models, adjusting for lung function parameters and IPF stage. Results. Patients with lower SH concentrations had significantly higher mortality (log-rank p = 0.012). SH group concentrations, but not TBARS, were independently and negatively associated with survival in multivariate models adjusting for %TLC, %FVC, %DLCO, and IPF stage (HR: 0.606, 95% CI: 0.443–0.830, p = 0.0018). Conclusions. Low plasma SH concentrations, reflecting systemic redox imbalance, are independently associated with increased mortality in newly diagnosed IPF. SH quantification represents a promising prognostic biomarker in IPF.

  • Open Access

    Malondialdehyde in cognitive impairment: A systematic review and meta-analysis

    by Stefano Zoroddu, Stefania Sedda, Arduino A. Mangoni, Ciriaco Carru, Angelo Zinellu


  • Open Access

    Next-Generation mRNA Vaccines in Melanoma: Advances in Delivery and Combination Strategies

    by Stefano Zoroddu, Luigi Bagella

    Messenger RNA (mRNA) vaccines have redefined cancer immunotherapy, offering unparalleled flexibility to encode tumor-specific antigens and to be adapted to individual mutational landscapes. Melanoma, with its high mutational burden and responsiveness to immune checkpoint blockade, has become the leading model for translating these advances into clinical benefit. Recent innovations in delivery—ranging from lipid nanoparticles and polymeric carriers to biomimetic hybrids and intratumoral administration—are dismantling long-standing barriers of stability, targeting, and immunogenicity. Clinical milestones, including the randomized phase IIb KEYNOTE-942, show that adding the personalized neoantigen vaccine mRNA-4157 (V940) to pembrolizumab prolonged recurrence-free survival versus pembrolizumab alone (HR 0.561, 95% CI 0.309–1.017; 18-month RFS 79% vs. 62%), with the ASCO 3-year update reporting 2.5-year RFS 74.8% vs. 55.6% and sustained distant metastasis-free survival benefit in resected high-risk melanoma. Parallel preclinical studies highlight the potential of multifunctional platforms co-delivering cytokines or innate agonists to reshape the tumor microenvironment and achieve durable systemic immunity. As artificial intelligence drives epitope selection and modular manufacturing accelerates personalization, mRNA vaccines may have the potential to transition from adjuncts to main therapies in melanoma and beyond.


  • Open Access

    The Double Life of microRNAs in Bone Sarcomas: Oncogenic Drivers and Tumor Suppressors

    by Stefano Zoroddu, Fabio Sias, Luigi Bagella

    Bone sarcomas, including Osteosarcoma, Ewing’s sarcoma, and Chondrosarcoma, are rare yet aggressive tumors with high metastatic potential and poor survival outcomes. Despite advances in surgical and chemotherapeutic techniques, these malignancies remain difficult to treat. They often exhibit resistance to conventional therapies and are associated with a limited prognosis for patients. MicroRNAs (miRNAs) have emerged as pivotal regulators of cancer biology, orchestrating crucial processes such as cell proliferation, apoptosis, and metastasis. Their double life as oncogenes or tumor suppressors underscores their significance in the pathogenesis of bone sarcomas. This review examines the multifaceted roles of miRNAs in these malignancies. By elucidating the complex networks affected by miRNA dysregulation, we seek to identify novel avenues for miRNA-based interventions. It is the intention of this work to stimulate future research and clinical strategies that exploit the potential of miRNAs to transform the management and outcomes of bone sarcomas.


  • Open Access

    A retrospective study on factors related to in-hospital mortality among patients with COVID-19, March 2020 to November 2021

    by Elisabetta Zinellu, Sara S Fois, Biagio Di Lorenzo, Stefano Zoroddu, Maria C Pau, Lorenzo Tassi, Barbara Piras, Alessandro G Fois, Ciriaco Carru, Arduino A Mangoni, et al.

    Introduction: Four years since the pandemic was declared, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains an important cause of illness around the world. Although many countries were able to overcome the health crisis at its peak, there are still individuals at high risk of a severe course of coronavirus disease 2019 (COVID-19). Therefore, it is important to continue research on the factors that could predict disease severity and adverse outcomes. Methodology: We conducted a retrospective study on 171 consecutive hospitalized cases of COVID-19 from March 2020 to November 2021. Past medical history, drug history, clinical and laboratory parameters on admission, and the choice of treatment during hospital stay were obtained and associated with in-hospital mortality. Results: Older age was significantly associated with mortality. Non-survivors also showed a significantly lower PaO2/FiO2 (P/F) ratio at the time of hospital admission; a lower lymphocyte count; and increased levels of white blood cell count, C-reactive protein (CRP), lactate dehydrogenase (LDH), D-dimer, and creatinine. Significant differences were also observed with regards to both long-term medications and treatments administered during hospital stay. Conclusions: Our findings highlight the importance of age, clinical features, biochemical biomarkers, and therapeutic interventions in predicting COVID-19 disease severity and outcomes.

  • Open Access

    Untangling the Role of MYC in Sarcomas and Its Potential as a Promising Therapeutic Target

    by Fabio Sias, Stefano Zoroddu, Rossana Migheli, Luigi Bagella

    MYC plays a pivotal role in the biology of various sarcoma subtypes, acting as a key regulator of tumor growth, proliferation, and metabolic reprogramming. This oncogene is frequently dysregulated across different sarcomas, where its expression is closely intertwined with the molecular features unique to each subtype. MYC interacts with critical pathways such as cell cycle regulation, apoptosis, and angiogenesis, amplifying tumor aggressiveness and resistance to standard therapies. Furthermore, MYC influences the tumor microenvironment by modulating cell–extracellular matrix interactions and immune evasion mechanisms, further complicating therapeutic management. Despite its well-established centrality in sarcoma pathogenesis, targeting MYC directly remains challenging due to its “undruggable” protein structure. However, emerging therapeutic strategies, including indirect MYC inhibition via epigenetic modulators, transcriptional machinery disruptors, and metabolic pathway inhibitors, offer new hope for sarcoma treatment. This review underscores the importance of understanding the intricate roles of MYC across sarcoma subtypes to guide the development of effective targeted therapies. Given MYC’s central role in tumorigenesis and progression, innovative approaches aiming at MYC inhibition could transform the therapeutic landscape for sarcoma patients, providing a much-needed avenue to overcome therapeutic resistance and improve clinical outcomes.


  • Open Access

    Osteopontin in rheumatic diseases: A systematic review and meta-analysis

    by Stefano Zoroddu, Biagio Di Lorenzo, Panagiotis Paliogiannis, Arduino A. Mangoni, Ciriaco Carru, Angelo Zinellu


  • Open Access

    Circulating Fetuin‐A concentrations in rheumatic diseases: a systematic review and meta‐analysis

    by Biagio Di Lorenzo, Stefano Zoroddu, Arduino A. Mangoni, Panagiotis Paliogiannis, Gian Luca Erre, Ciriaco Carru, Angelo Zinellu

    Background: Rheumatic diseases (RDs) include a broad group of disabling conditions with different phenotypes, from autoimmune to autoinflammatory, degenerative, metabolic or mixed manifestations. With the continuous efforts to identify therapeutic targets for new biologic drugs to treat overt clinical manifestations, research is also focusing on the discovery of new biomarkers to diagnose and manage early disease stages. In this context, we conducted a systematic review and meta‐analysis of Fetuin‐A (FtA), a glycoprotein synthesized by the liver that participates in several biological processes and has been proposed as a biomarker for several disorders, including rheumatoid arthritis.Methods: A systematic search in PubMed, Scopus and Web of Science, from inception to the 24th of August 2024, led to the identification of 13 manuscripts from 219 records; six additional studies were identified through reference hand‐search, for a total of 19 studies.Results: There was a significant decrease in FtA concentrations in RD patients (standardized mean difference, SMD = −.91; 95% CI −1.43 to −.39, p = .001), with no substantial contribution from any individual study nor publication bias. The effect size was significantly associated with erythrocyte sedimentation rate, various lipid fractions, geographical area of study conduction, study design and specific type of RD.Conclusion: In conclusion, our study identified significant reductions in FtA concentrations in RD patients versus healthy controls. These alterations were significantly associated with specific study and patient characteristics. Further research is required to identify the exact pathophysiological mechanisms underlying these alterations and the possible utility of measuring FtA for the diagnosis and management of RDs.


  • Open Access

    Vascular endothelial growth factor in inflammatory bowel disease: A systematic review and meta‐analysis

    by Stefano Zoroddu, Biagio Di Lorenzo, Panagiotis Paliogiannis, Arduino A. Mangoni, Ciriaco Carru, Angelo Zinellu

    Aim: Vascular endothelial growth factor (VEGF) is linked to inflammation and angiogenesis, indicating a possible role in inflammatory bowel disease (IBD) and its main clinical manifestations, Crohn's disease (CD) and ulcerative colitis (UC). This systematic review and meta‐analysis investigated studies assessing circulating VEGF concentrations in IBD patients and healthy controls, considering the effect of IBD type, sample type and geographical location.Methods: A systematic search identified 18 studies (28 group comparators) investigating 1741 IBD patients and 1291 controls. Data were extracted and analysed using standardized mean differences (SMD) with 95% confidence intervals (CI).Results: VEGF concentrations were significantly higher in IBD patients (SMD = .71, 95% CI .38 to 1.04; p < .001). UC patients showed higher VEGF concentrations than CD patients. Serum samples indicated significant VEGF elevations, unlike plasma samples. Significant VEGF increases were observed in studies conducted in Western Europe and Asia, but not in Eastern Europe. No significant differences were found between active and inactive disease.Conclusions: VEGF concentrations are elevated in IBD patients, with variations by disease type, sample type and geography. However, VEGF is not a reliable marker of disease activity. Future research should standardize methods and explore regional influences to enhance VEGF's clinical utility as a biomarker of IBD.


  • Open Access

    Dysregulation of miRNAs in Soft Tissue Sarcomas

    by Stefano Zoroddu, Angela Lucariello, Antonio De Luca, Luigi Bagella

    MicroRNAs (miRNAs) are pivotal regulators of gene expression, influencing key cellular processes such as proliferation, differentiation, apoptosis, and metastasis. In the realm of sarcomas—a diverse group of malignant tumors affecting soft tissues and bone sarcomas—miRNAs have emerged as crucial players in tumorigenesis and tumor progression. This review delves into the intricate roles of miRNAs across various soft tissue sarcoma subtypes, including rhabdomyosarcoma, liposarcoma, leiomyosarcoma, synovial sarcoma, fibrosarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma (UPS), and malignant peripheral nerve sheath tumor (MPNST). We explore how dysregulated miRNAs function as oncogenes or tumor suppressors, modulating critical pathways that define the aggressive nature of these cancers. Furthermore, we discuss the diagnostic and prognostic potential of specific miRNAs and highlight their promise as therapeutic targets. By understanding the miRNA-mediated regulatory networks, this review aims to provide a comprehensive overview of current research while pointing towards future directions for miRNA-based therapies. Our findings underscore the potential of miRNAs to transform the landscape of sarcoma treatment, offering hope for more precise, personalized, and effective therapeutic strategies.